Drug intelligence / Profile preview

BR206

Development stage: Unknown
Lead developer: BioRay
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BR206 is a monoclonal antibody developed by Hisun Bioray (BioRay Pharmaceutical) that targets the interleukin-4 receptor (IL-4R). It functions as an IL-4R antagonist, blocking the signaling pathways of both IL-4 and IL-13, which are central mediators of Type 2 inflammation. This mechanism is intended to treat various autoimmune and allergic conditions. As of recent pipeline updates, BR206 is in the IND-enabling or early clinical (Phase 1) stage of development.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on BR206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR206.

Explore the full profile